| 170. | Riedl, M. and Maurer, M.+: The road to better urticaria and angioedema management. J. Allergy Clin. Immunol. Pract. 2021: 9; 2243-2244. IF: 11.02 |
r.170
The road to better urticaria and angioedema management Read More »
|
169. |
Maurer, M.+, Khan, D. A., Komi, D. E. A., and Kaplan, A. P.: Biologics for the use in chronic spontaneous urticaria: when and which? J. Allergy Clin. Immunol. Pract. 2021: 9; 1067-1078. IF: 11.02 |
r.169
| 417. | Liao, S. L., Yu, M., Zhao, Z.*, and Maurer, M.+*: Case Report: Omalizumab for chronic spontaneous urticaria in pregnancy. Front. Immunol. 2021: 12; 652973. IF: 8.79 |
o.417
Case Report: Omalizumab for chronic spontaneous urticaria in pregnancy Read More »
| 168. | Metz, M.+ and Maurer, M.: Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy? Allergol. Select. 2021: 5; 89-95. IF: N/A |
r.168
Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy? Read More »
| 405. | Toubi, E., Giménez-Arnau, A. M., Maurer, M., and Vadasz, Z.+: Articular angioedema in patients with chronic spontaneous urticaria is frequently misdiagnosed as arthritis. J. Allergy Clin. Immunol. Pract. 2020: 8; 3232-3233. IF: 8.86 |
o.405
| 401. | Maurer, M.+, Giménez-Arnau, A., Ensina, L. F., Chu, C.-Y., Jaumont, X, and Tassinari, P.: Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organ. J. 2020: 13; 100460. IF: 4.08 |
o.401
| 400. | Maurer, M.+, Costa, C., Giménez-Arnau, A., Guillet, G., Labrador-Horrillo, M., Lapeere, H., Meshkova, R., Savic, S., and Chapman-Rothe, N.: Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study. Clin. Exp. Allergy 2020: 50; 1166-1175 IF: 5.02 |
o.400
| 388. | Weller, K.+, Donoso, T., Magerl, M., Aygören-Pürsün, E., Staubach, P., Martinez-Saguer, I., Hawro, T., Altrichter, S., Krause, K., Siebenhaar, F., Metz, M., Zuberbier, T., Freier, D., and Maurer, M.: Validation of the angioedema control test (AECT) – a patient reported outcome instrument for assessing angioedema control. J. Allergy Clin. Immunol. Pract. 2020: 8; 2050-2057. IF: 8.86 |
o.388
| 387. | Weller, K.+, Donoso, T., Magerl, M., Aygören-Pürsün, E., Staubach, P., Martinez-Saguer, I., Hawro, T., Altrichter, S., Krause, K., Siebenhaar, F., Metz, M., Zuberbier, T., Freier, D., and Maurer, M.: Development of the angioedema control test (AECT) – a patient reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy 2020: 75; 1165-1177. IF: 13.15 |
o.387
| 158. | Maurer, M.+, Eyerich, K., Eyerich, S., Ferrer, M., Gutermuth, J., Hartmann, K., Jakob, T., Kapp, A., Kolkhir, P., Larenas-Linnemann, D., Park, H.-S., Pejler, G., Sanchez-Borges, M., Schäkel, K., Simon, D., Simon, H.-U., Weller, K., Zuberbier, T., and Metz, M.: Urticaria: Collegium Internationale Allergologicum (CIA) update 2020. Int. Arch. Allergy Immunol. 2020: 181; 321-333. IF: 2.75 |
r.158
Urticaria: Collegium Internationale Allergologicum (CIA) update 2020 Read More »